Free Trial

Opthea (OPT) Stock Price, News & Analysis

Opthea logo
$4.36
0.00 (0.00%)
(As of 10/31/2024 ET)

About Opthea Stock (NASDAQ:OPT)

Key Stats

Today's Range
$4.21
$4.48
50-Day Range
$2.87
$5.13
52-Week Range
$1.61
$5.45
Volume
26,966 shs
Average Volume
24,531 shs
Market Capitalization
$254.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Buy

Company Overview

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Opthea Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
55th Percentile Overall Score

OPT MarketRank™: 

Opthea scored higher than 55% of companies evaluated by MarketBeat, and ranked 553rd out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Opthea has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Opthea has only been the subject of 1 research reports in the past 90 days.

  • Read more about Opthea's stock forecast and price target.
  • Earnings Growth

    Earnings for Opthea are expected to grow in the coming year, from ($1.40) to ($0.64) per share.

  • Percentage of Shares Shorted

    0.12% of the outstanding shares of Opthea have been sold short.
  • Short Interest Ratio / Days to Cover

    Opthea has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Opthea has recently increased by 9.97%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Opthea does not currently pay a dividend.

  • Dividend Growth

    Opthea does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.12% of the outstanding shares of Opthea have been sold short.
  • Short Interest Ratio / Days to Cover

    Opthea has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Opthea has recently increased by 9.97%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Opthea has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • MarketBeat Follows

    1 people have added Opthea to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Opthea insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.20% of the stock of Opthea is held by insiders.

  • Percentage Held by Institutions

    55.95% of the stock of Opthea is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Opthea's insider trading history.
Receive OPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opthea and its competitors with MarketBeat's FREE daily newsletter.

OPT Stock News Headlines

Opthea Wet AMD Program to be Presented at Innovate Retina
The real reason Elon is fully endorsing Trump
Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.
Opthea Joins the S&P/ASX 300 Index
See More Headlines

OPT Stock Analysis - Frequently Asked Questions

Opthea's stock was trading at $2.95 at the beginning of the year. Since then, OPT shares have increased by 47.8% and is now trading at $4.36.
View the best growth stocks for 2024 here
.

Opthea (OPT) raised $161 million in an initial public offering on Friday, October 16th 2020. The company issued 9,300,000 shares at a price of $17.26 per share. Citigroup and SVB Leerink served as the underwriters for the IPO and Oppenheimer & Co. and Truist Securities were co-managers.

Shares of OPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Opthea investors own include PayPal (PYPL), Sunrun (RUN), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), QUALCOMM (QCOM), Ross Stores (ROST) and Zendesk (ZEN).

Company Calendar

Today
10/31/2024
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OPT
Fax
N/A
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.00
High Stock Price Target
$12.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+175.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$124,666.00
Book Value
($1.30) per share

Miscellaneous

Free Float
56,526,000
Market Cap
$254.60 million
Optionable
Not Optionable
Beta
1.17
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

This page (NASDAQ:OPT) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners